Parexel Extends Strategic Partnership with Medidata to Enhance Delivery of Decentralized Clinical Trials

New York – February 4, 2022 –  Medidata, a Dassault Systèmes company, announced today that Parexel, a leading global clinical research organization (CRO) focused on development and delivery of innovative new therapies to advance patient health, is extending their 15-year global strategic partnership. This builds upon the trusted relationship between the two companies and sets the goal of jointly pioneering a new era of decentralized clinical trial technology (DCT) for the life sciences industry.

“Parexel’s priority focus is on providing patient-centered solutions that enhance the clinical trial experience and make participation more accessible to everyone,” said Clare Grace, Ph.D., Chief Patient Officer at Parexel. “Medidata’s DCT technologies further support our efforts in a market where nearly 75% of proposals include at least a hybrid trial model. We’re pleased to partner with them as we continue to expand our offerings in this area.” 

Anthony Costello, Patient Cloud CEO at Medidata, added: “The COVID-19 pandemic showed us that we can leverage DCT technologies to expedite and enhance the entire clinical trials process. The relationship with Parexel represents an enormous opportunity to forever redefine the patient experience and development timelines for the development of new medicines and vaccines.”

Parexel also participates in Medidata’s Early Adopter DCT program leveraging its unified platform, the myMedidata patient portal, Sensor Cloud, and Medidata’s proprietary Patient Centricity by Design program. Parexel provides feedback and insights to help ensure the portal meets the needs of patients, sites, and sponsors. With myMedidata, patients can virtually access all of their clinical trial needs through one web-based portal, removing the need for provisioned devices and improving clinical trial experiences.

Medidata is a wholly owned subsidiary of Dassault Systèmes, which with its 3DEXPERIENCE platform is positioned to lead the digital transformation of life sciences in the age of personalized medicine with the first end-to-end scientific and business platform, from research to commercialization.